Radiolabeled anti–prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer (CRPC).

Management expects typical Q3 to Q4 operating ratio degradation to be in the "300 to 400 basis point" range, with Batteh noting, "With October trending a little bit lower this year than what we've ...

Impact of interstitial brachytherapy (IB) or radical prostatectomy (RP) on quality of life (QL) of patients (pts) treated for localized prostate cancer (LPC): Medium-term outcomes from a prospective ...

HANOVER, Pa.--(BUSINESS WIRE)--Utz Brands, Inc. (NYSE: UTZ) and its affiliated entities (“Utz” or the “Company”), a leading U.S. manufacturer of branded salty snacks, today announced several network ...